Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene

被引:10
作者
Gao, Ming [1 ,2 ]
Zhu, Bin [3 ]
Xu, Zhe [4 ]
Liu, Shujun [1 ,2 ]
Liu, Jiajia [1 ,2 ]
Zhang, Guojun [1 ,2 ]
Gao, Yang [5 ]
Fan, Yubo [5 ]
Kang, Xixiong [1 ,2 ,5 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Lab Diag Ctr, Beijing 100050, Peoples R China
[2] Beijing Engn Res Ctr Immunol Reagents & Clin Res, Beijing 100050, Peoples R China
[3] Capital Med Univ, Beijing Tiantan Hosp, Dept Pharm, Beijing 100050, Peoples R China
[4] Beijing Tiantan Hosp, Monogen Dis Res Ctr Neurol Disorders, Beijing 100050, Peoples R China
[5] Beihang Univ, Lab Biol Sci & Med Engn, Beijing 100191, Peoples R China
关键词
Insulin-like growth factor binding protein-3; Single nucleotide polymorphism; Acromegaly; Pituitary adenoma; Case-control study; FACTOR-BINDING PROTEIN-3; CANCER-RISK; CLINICAL-PRACTICE; A/C POLYMORPHISM; PROSTATE-CANCER; BLADDER-CANCER; SERUM-LEVELS; DISEASE;
D O I
10.1186/s12881-018-0698-2
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: It has been reported that the single nucleotide polymorphism (SNP) rs2854744 at the - 202 locus of insulin-like growth factor binding protein-3 (IGFBP3) is associated with serum levels and a number of malignancies. However, the effect of IGFBP3 gene polymorphism on acromegaly is less clear. Therefore, in the current study, we aimed to investigate whether the -202A/C polymorphism of IGFBP3 constitutes a risk factor for acromegaly. Methods: The study included 102 acromegalic patients and 143 control subjects in Beijing Tiantan Hospital. The genotyping of IGFBP3 was carried out using the MassARRAY method. Serum IGFBP3 concentrations were also determined. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the associations of genetic polymorphisms with the development of acromegaly and its different subtypes. Results: The study revealed that the C allele of rs2854744 was associated with a reduced risk of acromegaly (OR 0.594, 95% CI 0.388-0.909), as well as with the female (OR 0.385, 95% CI 0.206-0.72), macroadenoma (OR 0.557, 95% CI 0.347-0.893) and monotherapy (OR 0.512, 95% CI 0.316-0.828) subgroups under the additive model. A higher serum IGFBP3 level was observed in patients with the AA genotype, but this difference was not significant (P = 0.331). Conclusion: This study is one of the first to show that the IGFBP3 polymorphism may have an influence on serum levels and that the C allele of rs2854744 is associated with a reduced risk of acromegaly. This correlation was more prominent in females, those with large tumours and those treated with monotherapy in a Chinese population. Genetic polymorphism of IGFBP3 may be involved in the development of acromegaly.
引用
收藏
页数:7
相关论文
共 25 条
[11]   Influence of growth hormone receptor (GHR) exon 3 and-202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly [J].
Jallad, Raquel S. ;
Trarbach, Ericka B. ;
Duarte, Felipe H. ;
Jorge, Alexander A. L. ;
Bronstein, Marcello D. .
PITUITARY, 2015, 18 (05) :666-673
[12]   Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease [J].
Jogie-Brahim, Sherryline ;
Feldman, David ;
Oh, Youngman .
ENDOCRINE REVIEWS, 2009, 30 (05) :417-437
[13]   IGFBP-3: A cell fate pivot in cancer and disease [J].
Johnson, Michael A. ;
Firth, Sue M. .
GROWTH HORMONE & IGF RESEARCH, 2014, 24 (05) :164-173
[14]   Acromegaly: An Endocrine Society Clinical Practice Guideline [J].
Katznelson, Laurence ;
Laws, Edward R., Jr. ;
Melmed, Shlomo ;
Molitch, Mark E. ;
Murad, Mohammad Hassan ;
Utz, Andrea ;
Wass, John A. H. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (11) :3933-3951
[15]   AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY-2011 UPDATE: EXECUTIVE SUMMARY [J].
Katznelson, Laurence ;
Atkinson, John L. D. ;
Cook, David M. ;
Ezzat, Shereen Z. ;
Hamrahian, Amir H. ;
Miller, Karen K. .
ENDOCRINE PRACTICE, 2011, 17 (04) :636-646
[16]   IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer [J].
Mayo, Juan C. ;
Hevia, David ;
Quiros-Gonzalez, Isabel ;
Rodriguez-Garcia, Aida ;
Gonzalez-Menendez, Pedro ;
Cepas, Vanesa ;
Gonzalez-Pola, Ivan ;
Sainz, Rosa M. .
JOURNAL OF PINEAL RESEARCH, 2017, 62 (01)
[17]   Promoter-202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk [J].
Moon, JW ;
Chang, YS ;
Ahn, CW ;
Yoo, KN ;
Shin, JH ;
Kong, JH ;
Kim, YS ;
Chang, J ;
Kim, SK ;
Kim, HJ ;
Kim, SK .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) :353-356
[18]   Polymorphism in IGFBP3 gene is associated with prostate cancer risk: an updated meta-analysis [J].
Qie, Yunkai ;
Nian, Xuewu ;
Liu, Xuesen ;
Hu, Hailong ;
Zhang, Changwen ;
Xie, Linguo ;
Han, Ruifa ;
Wu, Changli ;
Xu, Yong .
ONCOTARGETS AND THERAPY, 2016, 9 :4163-4171
[19]   Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments [J].
Ramos-Levi, Ana M. ;
Marazuela, Monica ;
Paniagua, Amalia ;
Quinteiro, Celsa ;
Riveiro, Javier ;
Alvarez-Escola, Cristina ;
Lucas, Tomas ;
Blanco, Concepcion ;
de Miguel, Paz ;
Martinez de Icaya, Purificacion ;
Pavon, Isabel ;
Bernabeu, Ignacio .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) :115-122
[20]   The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene [J].
Safarinejad, Mohammad Reza ;
Shafiei, Nayyer ;
Safarinejad, Shiva H. .
ARCHIVES OF TOXICOLOGY, 2011, 85 (10) :1209-1218